Epidemiology, Treatment Patterns, and Clinical Outcomes Among Patients With Acquired Thrombotic Thrombocytopenic Purpura (Attp) in the United States: An Electronic Health Records Analysis

Background: Fever, thrombocytopenia, hemolysis, pentad failing kidneys, anaemia, and neurological impairment has historically been used to describe bleeding as the blood syndrome “thrombotic thrombocytopenic purpura” (TTP), a type of hemolytic anaemia caused by microangiopathy. TTP is an uncommon condition, and it is unclear exactly how often it is? According to studies, incidence per million depends on where individuals live. TTP can occur in youth with congenital forms, however it mostly strikes adults over the age of 40. The two organ systems most frequently impacted by TTP are the nerve system of the body (CNS) and kidneys. Because TTP is a serious medical condition with a 90% fatality grad if untreated, prompt diagnosis is crucial. Initial therapy is effective in around 80% of patients, and post-treatment mortality is between 10% and 15%. Objectives: The study aimed to summarize current evidences regarding epidemiology and outcomes of Thrombotic Thrombocytopenic Purpura therapy (TTP). Methods: For article selection, the PubMed database and EBSCO Information Services were used. All articles relevant with our topic and other articles were used in our review. Other articles that were not related to this field were excluded. The data was extracted in a specific format that was reviewed by the group members. Conclusion: Older patients had longer Immune thrombotic thrombocytopenic purpura (iTTP) episodes and died at higher rates than younger patients. iTTP patients have a considerable increase in chance of illness and demise, while receiving TPE and immunosuppressants, which necessitate the need for more potent treatments. Moreover, they are more likely to have secondary thrombotic microangiopathies than primary microangiopathies due to several causes. Depending on the origin of thrombotic microangiopathies, there are different risks associated with dialysis, neurologic and cardiac issues, and mortality. Mortality rate are low for patients who received hospital care with low rate of complications.

show abstract

“…Epidemiology and Administration outcomes of Thrombotic Thrombocytopenic Purpura (TTP): Review article Lee et al 2017 [19].…”

Section: Objective Andmethodology Outcomesmentioning

confidence: 99%

“…Adeyemi et al 2021 [19]. This long-term retrospective observational analysis of the Optum-Humedica database included patients with aTTP diagnosis from October 2015 to December 2019 ADAMTS13 activities of 10% or at least one aTTP event must have been recorded in the database.…”

Section: Ayoadementioning

confidence: 99%

Epidemiology and Administration outcomes of Thrombotic Thrombocytopenic Purpura (TTP): Review article

Hussein¹,

Baqir

Waznah

et al. 2022

SMHJ

View full text Add to dashboard Cite

show abstract

A Systematic Review of the Epidemiology and Disease Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura

Du,

Cristarella,

Goyer

et al. 2024

JBM

View full text Add to dashboard Cite

Congenital (cTTP) and immune-mediated (iTTP) thrombotic thrombocytopenic purpura are serious and rare clotting disorders resulting from a deficiency in the ADAMTS13 enzyme. A systematic review was conducted using the Ovid ® MEDLINE & Embase databases to synthesize the epidemiology and burden of cTTP and iTTP worldwide (from January 1, 2010, to February 6, 2020, with an update that covered the period January 1, 2020–February 11, 2022). Outcomes of interest were incidence and prevalence of TTP, incidence of acute episodes, mortality, burden of illness (eg complications, healthcare utilization, patient-reported outcomes) and disease management. A total of 221 eligible observational studies were included. The incidence rate of acute episodes ranged from 0.19–0.35 person-years in adult patients with cTTP, and 1.81–3.93 per million persons per year for iTTP in the general population. Triggers of acute episodes were similar for cTTP and iTTP, with pregnancy and infection the most commonly observed. Exacerbation in patients with iTTP varied widely, ranging from 2.4–63.1%. All-cause mortality was observed in 0–13.4% of patients with cTTP, across studies and follow-up periods, and in 1.1% (median follow-up: 0.4 years) to 18.8% (1 year) of patients with iTTP during acute episodes. Cardiovascular, renal, and neurological disease were common complications. TTP also led to work disturbances, feelings of anxiety and depression, and general activity impairment. TTP treatment regimens used were generally reflective of current treatment guidelines. The evidence identified describes a high patient burden, highlighting the need for effective treatment regimens leading to improvements in outcomes. Considerable evidence gaps exist, particularly for disease epidemiology, patient-reported outcomes, costs of disease management, and associated healthcare resource utilization. This review may help increase disease awareness and highlights the need for additional real-world studies, particularly in geographical regions outside the United States and Western Europe.

show abstract

Epidemiology, Treatment Patterns, and Clinical Outcomes Among Patients With Acquired Thrombotic Thrombocytopenic Purpura (Attp) in the United States: An Electronic Health Records Analysis

Cited by 2 publications

References 0 publications

Epidemiology and Administration outcomes of Thrombotic Thrombocytopenic Purpura (TTP): Review article

Epidemiology and Administration outcomes of Thrombotic Thrombocytopenic Purpura (TTP): Review article

A Systematic Review of the Epidemiology and Disease Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura

Contact Info

Product

Resources

About